Skip to content
Biodatica
Start free

Astellas Pharma Global Development, Inc.

Los Angeles, California

OncologyPhase IListed · ALPMY

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Sign in to watch

What changed

Phase I trial registered: A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4

yesterdayTrial registeredJul 17, 2026Source filing (opens the source filing in a new tab)

Momentum

86no change

Momentum 86 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase I

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    Study registered

    Feb 20, 2026

    Stargardt Disease, Stargardt Macular Dystrophy, Stargardt-like Macular Dystrophy · RECRUITING · sponsor: Astellas Pharma Global Development, Inc. · A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults

    ClinicalTrials.gov · NCT07425574 (opens the source filing in a new tab)

  2. Trial

    Study registered

    Sep 10, 2025

    Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma Cancer, Metastatic Gastric Adenocarcinoma Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma · AVAILABLE · sponsor: Astellas Pharma Global Development, Inc. · Early Access Program for Zolbetuximab

    ClinicalTrials.gov · NCT06048081 (opens the source filing in a new tab)

  3. Trial

    PHASE1 registered

    May 14, 2014

    Metastatic Urothelial Cancer and Other Malignant Solid Tumors · COMPLETED · sponsor: Astellas Pharma Global Development, Inc. · A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4

    ClinicalTrials.gov · NCT02091999 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources